LianBio (LIAN) Competitors $0.05 0.00 (0.00%) As of 08/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendFDA EventsInsider TradesSEC FilingsTrendsBuy This Stock LIAN vs. ELEV, RVPH, CING, CASI, BCAB, RLYB, PMN, ATNF, AYTU, and FNCHShould you be buying LianBio stock or one of its competitors? The main competitors of LianBio include Elevation Oncology (ELEV), Reviva Pharmaceuticals (RVPH), Cingulate (CING), CASI Pharmaceuticals (CASI), BioAtla (BCAB), Rallybio (RLYB), Promis Neurosciences (PMN), 180 Life Sciences (ATNF), Aytu BioPharma (AYTU), and Finch Therapeutics Group (FNCH). These companies are all part of the "pharmaceutical products" industry. LianBio vs. Its Competitors Elevation Oncology Reviva Pharmaceuticals Cingulate CASI Pharmaceuticals BioAtla Rallybio Promis Neurosciences 180 Life Sciences Aytu BioPharma Finch Therapeutics Group LianBio (NASDAQ:LIAN) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk. Which has more volatility and risk, LIAN or ELEV? LianBio has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Which has stronger valuation & earnings, LIAN or ELEV? Elevation Oncology is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLianBioN/AN/A-$110.29M-$0.81-0.06Elevation OncologyN/AN/A-$44.49M-$0.82-0.45 Does the media refer more to LIAN or ELEV? In the previous week, LianBio's average media sentiment score of 0.00 equaled Elevation Oncology'saverage media sentiment score. Company Overall Sentiment LianBio Neutral Elevation Oncology Neutral Is LIAN or ELEV more profitable? LianBio's return on equity of -33.17% beat Elevation Oncology's return on equity.Company Net Margins Return on Equity Return on Assets LianBioN/A -33.17% -30.19% Elevation Oncology N/A -74.68%-48.14% Do insiders & institutionals believe in LIAN or ELEV? 74.8% of LianBio shares are owned by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are owned by institutional investors. 7.6% of LianBio shares are owned by insiders. Comparatively, 8.1% of Elevation Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer LIAN or ELEV? Elevation Oncology has a consensus target price of $2.62, indicating a potential upside of 616.89%. Given Elevation Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Elevation Oncology is more favorable than LianBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Elevation Oncology 0 Sell rating(s) 11 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryElevation Oncology beats LianBio on 6 of the 10 factors compared between the two stocks. Get LianBio News Delivered to You Automatically Sign up to receive the latest news and ratings for LIAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIAN vs. The Competition Export to ExcelMetricLianBioBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.43M$138.02M$5.58B$9.86BDividend YieldN/A3.74%4.64%4.14%P/E Ratio-0.063.7630.5525.47Price / SalesN/A4,227.82457.79104.67Price / CashN/A13.1937.7258.50Price / Book0.0242.198.466.04Net Income-$110.29M-$90.99M$3.26B$265.10M7 Day PerformanceN/A0.09%2.59%2.11%1 Month PerformanceN/A3.05%5.07%3.27%1 Year PerformanceN/A180.00%42.40%25.63% LianBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIANLianBioN/A$0.05flatN/A-84.5%$5.43MN/A-0.06110ELEVElevation Oncology2.285 of 5 stars$0.37flat$2.62+616.9%N/A$21.62MN/A-0.4540News CoverageRVPHReviva Pharmaceuticals3.3744 of 5 stars$0.46+2.8%$9.00+1,856.5%-43.8%$21.48MN/A-0.585News CoverageCINGCingulate3.2101 of 5 stars$4.09+1.0%$26.00+535.7%+43.5%$21.32MN/A-0.4820News CoverageGap UpCASICASI Pharmaceuticals4.3081 of 5 stars$1.81+4.6%$4.00+121.0%-72.2%$21.28M$28.54M-0.71180News CoverageUpcoming EarningsGap DownBCABBioAtla1.8312 of 5 stars$0.37+2.1%$5.00+1,251.0%-73.4%$21.18M$11M-0.3460News CoverageEarnings ReportAnalyst DowngradeAnalyst RevisionRLYBRallybio2.4033 of 5 stars$0.50+1.3%$10.00+1,885.3%-54.2%$20.77M$640K-0.5440News CoverageEarnings ReportPMNPromis Neurosciences2.5769 of 5 stars$0.70+11.5%$4.33+519.0%-42.6%$20.53MN/A-14.005Earnings ReportUpcoming EarningsGap DownATNF180 Life Sciences0.9452 of 5 stars$10.24+206.6%N/A+502.4%$20.17MN/A-0.687News CoverageGap UpHigh Trading VolumeAYTUAytu BioPharma3.7539 of 5 stars$2.25+0.4%$10.00+344.4%-5.1%$20.11M$81.66M-3.13160FNCHFinch Therapeutics GroupN/A$12.25+0.1%N/A+28.9%$19.67MN/A-1.39190 Related Companies and Tools Related Companies ELEV Alternatives RVPH Alternatives CING Alternatives CASI Alternatives BCAB Alternatives RLYB Alternatives PMN Alternatives ATNF Alternatives AYTU Alternatives FNCH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIAN) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LianBio Please log in to your account or sign up in order to add this asset to your watchlist. Share LianBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access